# OnCo record sezary-syndrome (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/sezary-syndrome/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "sezary-syndrome" ;
  schema:name "Sezary syndrome"@en ;
  schema:alternateName "Sézary syndrome"@en, "Sezary disease"@en, "Sézary disease"@en, "Leukaemic cutaneous T-cell lymphoma"@en, "Sezary syndrome (erythroderma with blood involvement)"@en ;
  schema:description "Sezary syndrome is the leukaemic form of skin lymphoma: the whole skin turns red and scaly, the lymph nodes swell, and malignant T cells circulate in the blood. It is treated to control rather than cure, with photopheresis, the antibody mogamulizumab, and drugs such as bexarotene and interferon, and a stem cell transplant is the only treatment that can cure it in fit patients."@en ;
  schema:url <https://onco.cc/cancers/sezary-syndrome/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/S%C3%A9zary_disease> ;
  schema:citation <https://www.cancer.gov/types/lymphoma/patient/mycosis-fungoides-treatment-pdq>, <https://doi.org/10.1038/s41375-022-01620-2>, <https://doi.org/10.1016/j.ejca.2023.113343>, <https://doi.org/10.1016/j.ejca.2017.02.027>, <https://doi.org/10.1001/archderm.143.7.854> ;
  onco:tag "subtype-page", "wave4", "haematologic", "rare" ;
  onco:related <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/t-cell-prolymphocytic-leukaemia/>, <https://onco.cc/cancers/primary-cutaneous-marginal-zone-lymphoma/>, <https://onco.cc/biomarkers/ig-tcr-clonality/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/technologies/clonality-testing/> ;
  onco:targets <https://onco.cc/targets/ccr4/>, <https://onco.cc/targets/cd52/>, <https://onco.cc/targets/stat3/>, <https://onco.cc/targets/stat5/>, <https://onco.cc/targets/jak1/>, <https://onco.cc/targets/jak3/> ;
  onco:drugs <https://onco.cc/drugs/mogamulizumab/>, <https://onco.cc/drugs/methoxsalen-ecp/>, <https://onco.cc/drugs/bexarotene/>, <https://onco.cc/drugs/interferon-alfa/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/pralatrexate/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/romidepsin/>, <https://onco.cc/drugs/vorinostat/>, <https://onco.cc/drugs/resminostat/>, <https://onco.cc/drugs/alemtuzumab/>, <https://onco.cc/drugs/chlorambucil/> ;
  onco:pathways <https://onco.cc/pathways/jak-stat/> ;
  onco:terms <https://onco.cc/terms/allogeneic-transplant/>, <https://onco.cc/terms/lymphoma-tx-skin-directed-therapy/>, <https://onco.cc/terms/lymphoma-tx-pjp-and-infection-prophylaxis/>, <https://onco.cc/terms/lymphoma-bio-lineage-antigen-cost/> ;
  onco:trials <https://onco.cc/trials/mavoric/>, <https://onco.cc/trials/nct04930653/>, <https://onco.cc/trials/nct02953301/> ;
  onco:standardOfCare <https://onco.cc/drugs/methoxsalen-ecp/>, <https://onco.cc/drugs/bexarotene/>, <https://onco.cc/drugs/interferon-alfa/>, <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/>, <https://onco.cc/drugs/mogamulizumab/>, <https://onco.cc/trials/mavoric/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/pralatrexate/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/romidepsin/>, <https://onco.cc/drugs/vorinostat/>, <https://onco.cc/terms/allogeneic-transplant/>, <https://onco.cc/drugs/methoxsalen-ecp/>, <https://onco.cc/drugs/mogamulizumab/>, <https://onco.cc/drugs/bexarotene/>, <https://onco.cc/drugs/interferon-alfa/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/romidepsin/>, <https://onco.cc/drugs/alemtuzumab/>, <https://onco.cc/drugs/chlorambucil/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/key-papers/paper-mavoric-mogamulizumab-lancet-oncol-2018/>, <https://onco.cc/terms/lymphoma-tx-skin-directed-therapy/>, <https://onco.cc/terms/lymphoma-tx-pjp-and-infection-prophylaxis/> .